Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
Paul F. Pinsky(National Cancer Institute), Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Anthony B. Miller(University of Toronto), Amanda Black(St. Elizabeth's Hospital), Howard L. Parnes(National Institutes of Health), E. David Crawford(University of Colorado Denver), Robert L. Grubb, Douglas J. Reding(Ascension)
Cited by 22
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k